Synagis (MedImmune Inc)
Synagis (MedImmune Inc) Brand names, Synagis (MedImmune Inc) Analogs
Synagis (MedImmune Inc) Brand Names Mixture
- No information avaliable
Synagis (MedImmune Inc) Chemical_Formula
No information avaliable
Synagis (MedImmune Inc) RX_link
http://www.rxlist.com/cgi/generic2/palivizumab.htm
Synagis (MedImmune Inc) fda sheet
Synagis (MedImmune Inc) msds (material safety sheet)
Synagis (MedImmune Inc) Synthesis Reference
sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.
Synagis (MedImmune Inc) Molecular Weight
No information avaliable
Synagis (MedImmune Inc) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Synagis (MedImmune Inc) H2O Solubility
No information avaliable
Synagis (MedImmune Inc) State
Liquid
Synagis (MedImmune Inc) LogP
No information avaliable
Synagis (MedImmune Inc) Dosage Forms
Powder for solution
Synagis (MedImmune Inc) Indication
For treatment of respiratory diseases casued by respiratory syncytial virus
Synagis (MedImmune Inc) Pharmacology
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Synagis (MedImmune Inc) Absorption
No information avaliable
Synagis (MedImmune Inc) side effects and Toxicity
No information avaliable
Synagis (MedImmune Inc) Patient Information
No information avaliable
Synagis (MedImmune Inc) Organisms Affected
No information avaliable
